Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD40 expression in bladder cancer.

P W Cooke1, N D James, R Ganesan

  • 1CRC Institute for Cancer Studies, University of Birmingham, Birmingham, U.K. peter.cooke@virgin.net

The Journal of Pathology
|July 9, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring the Knowledge Gap: A Scoping Review of Nutrition Insecurity and Related Factors Among Black Cancer Survivors in the United States.

Ecology of food and nutrition·2026
Same author

People with prior tuberculosis have accelerated frailty and differential survival into older age: a cross-sectional analysis in Southern Africa.

The Journal of infectious diseases·2026
Same author

The experiences and impact of the COVID-19 pandemic on young carers: practice implications and planning for future health emergencies.

Child and adolescent psychiatry and mental health·2024
Same author

How did UK social distancing restrictions affect the lives of women experiencing intimate partner violence during the COVID-19 pandemic? A qualitative exploration of survivor views.

BMC public health·2023
Same author

The APPLE Tree programme: Active Prevention in People at risk of dementia through Lifestyle, bEhaviour change and Technology to build REsiliEnce-randomised controlled trial.

Trials·2022
Same author

Factors affecting the mental health of pregnant women using UK maternity services during the COVID-19 pandemic: a qualitative interview study.

BMC pregnancy and childbirth·2022
Same journal

Knowledge gaps in tubular gut tumours: a critical appraisal of the 6th edition of the World Health Organization classification of tumours.

The Journal of pathology·2026
Same journal

Tumor Invasive Border Index (TIBI) in colorectal cancer: linking infiltrative morphology to molecular insights.

The Journal of pathology·2026
Same journal

Lipodystrophy and adipose tissue recovery are mediated by the Wnt/lipogenesis axis during skin fibrosis.

The Journal of pathology·2026
Same journal

Optical mapping reveals a higher level of large-scale structural variants in a family with paternally transmitted myotonic dystrophy and independent Parkinson's disease.

The Journal of pathology·2026
Same journal

FTO-mediated m6A modification of protein disulfide-isomerase activates VEGFA-VEGFR2 to suppress programmed cell death in osteosarcoma.

The Journal of pathology·2026
Same journal

Dopamine inhibits retinal pathological neovascularization in the oxygen-induced retinopathy mouse model.

The Journal of pathology·2026
See all related articles

CD40 receptor expression is common in bladder cancers, particularly in early stages (Ta/T1). This finding suggests CD40 may influence cancer development and response to immunotherapy, like BCG treatment.

Area of Science:

  • Immunology
  • Oncology
  • Urothelial Carcinomas

Background:

  • The CD40 receptor plays a key role in immune responses and is found on various cancer cells, indicating potential significance in cancer biology.
  • CD40's role in bladder cancer development and treatment is an area of active research interest.

Purpose of the Study:

  • To investigate CD40 receptor expression in bladder transitional cell carcinomas.
  • To correlate CD40 expression with prognostic markers and clinical outcomes.

Main Methods:

  • Immunohistochemical analysis of CD40 expression in 131 bladder transitional cell carcinomas.
  • Assessment of correlations with clinicopathological variables, including tumor stage, grade, Bcl-2, and p53 expression.

Main Results:

Related Experiment Videos

  • CD40 was expressed in 78% of bladder tumors, significantly associated with lower stage and grade (p<0.001).
  • Ta and T1 tumors showed higher CD40 positivity (89%) compared to T2-T4 tumors (62%). Normal urothelium was largely CD40-negative.
  • CD40 expression did not correlate with Bcl-2 or p53, nor was it an independent prognostic marker.

Conclusions:

  • CD40 expression is linked to less aggressive bladder cancer phenotypes and may contribute to favorable responses to BCG immunotherapy.
  • The findings support exploring CD40/CD40 ligand-based immunotherapies for bladder cancer treatment.